Cargando…

Outcomes of surgery and subsequent therapy for central nervous system oligoprogression in EGFR-mutated NSCLC patients

BACKGROUND: Oligoprogression is an emerging issue in patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC). However, the surgical treatment for central nervous system (CNS) oligoprogression is not widely discussed. We investigated the outcomes of craniotomy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Perng, Pang-Shuo, Hsu, Heng-Juei, Lee, Jung-Shun, Wang, Liang-Chao, Huang, Chih-Yuan, Tien, Chih-Hao, Lai, Yu-Hsuan, Su, Po-Lan, Hsu, Hao-Hsiang, Chen, Liang-Yi, Lee, Po-Hsuan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10675964/ https://www.ncbi.nlm.nih.gov/pubmed/38007448 http://dx.doi.org/10.1186/s12957-023-03248-7

Ejemplares similares

Technical Case Report of a Cranioplasty With ex vivo Frozen Ostoblastic Bone Graft From Large Skull Metastasis
por: Perng, Pang-Shuo, et al.
Publicado: (2021)

Recurrent inverted papilloma coexisted with skull base lymphoma: A case report
por: Hsu, Heng Juei, et al.
Publicado: (2021)

Safety and Efficacy of Sorafenib and Lenvatinib in Patients Who Underwent Surgery or Whole-Brain Radiotherapy for Brain Metastasis of Hepatocellular Carcinoma
por: Perng, Pang-Shuo, et al.
Publicado: (2022)

Characterizing the Impact of Compression Duration and Deformation-Related Loss of Closure Force on Clip-Induced Spinal Cord Injury in Rats
por: Lee, Po-Hsuan, et al.
Publicado: (2023)

Systemic Therapy for Oligoprogression in Patients with Metastatic NSCLC Harboring Activating EGFR Mutations
por: Rossi, Antonio, et al.
Publicado: (2022)

First-line continual EGFR-TKI plus local ablative therapy demonstrated survival benefit in EGFR-mutant NSCLC patients with oligoprogressive disease
por: Xu, Qinghua, et al.
Publicado: (2019)

The Role of Neutrophil-to-Lymphocyte Ratio in Advanced EGFR-Mutant NSCLC Patients Treated with First-Line Osimertinib
por: Chen, Kuan-Chih, et al.
Publicado: (2023)

Is there a weekend effect in spine surgery?: A systematic review and meta-analysis of postoperative outcomes
por: Chang, Yu, et al.
Publicado: (2023)

Management of Oligoprogression in Patients with Metastatic NSCLC Harboring ALK Rearrangements
por: Pisano, Chiara, et al.
Publicado: (2022)

Treatment strategies based on different oligoprogressive patterns after immunotherapy failure in metastatic NSCLC
por: Xuzhang, Wendi, et al.
Publicado: (2023)

Quantification of vessel separation using the carotid-jugular angle to predict the nerve origin of neck peripheral nerve sheath tumours: a pooled analysis of cases from the literature and a single-center cohort
por: Wong, Chia-En, et al.
Publicado: (2023)

Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLC
por: Ju, Jia-Shiuan, et al.
Publicado: (2023)

Various impacts of driver mutations on the PD-L1 expression of NSCLC
por: Chu, Cheng-Hsiang, et al.
Publicado: (2022)

Histological Transformation after Acquired Resistance to the Third-Generation EGFR-TKI in Patients with Advanced EGFR-Mutant Lung Adenocarcinoma
por: Lee, Po-Hsin, et al.
Publicado: (2022)

The impact of EGFR mutations on the incidence and survival of stages I to III NSCLC patients with subsequent brain metastasis
por: Chang, Wei-Yuan, et al.
Publicado: (2018)

Outcome of Wingspan Stent Using Aggressive Post-stent Balloon Dilation for Intracranial Atherosclerosis Stenosis
por: Perng, Pang-Shuo, et al.
Publicado: (2021)

Spinal giant cell-rich osteosarcoma-diagnostic dilemma and treatment strategy: A case report
por: Tseng, Chen-Sheng, et al.
Publicado: (2022)

The impact of different first-line EGFR-TKIs on the clinical outcome of sequential osimertinib treatment in advanced NSCLC with secondary T790M
por: Huang, Yen-Hsiang, et al.
Publicado: (2021)

Subsequent treatments beyond progression on osimertinib in EGFR-mutated NSCLC and leptomeningeal metastases
por: Zheng, Mei-Mei, et al.
Publicado: (2022)

Publisher Correction: The impact of different first-line EGFR-TKIs on the clinical outcome of sequential osimertinib treatment in advanced NSCLC with secondary T790M
por: Huang, Yen-Hsiang, et al.
Publicado: (2021)

Association of Periodontitis and Subsequent Depression: A Nationwide Population-Based Study
por: Hsu, Chih-Chao, et al.
Publicado: (2015)

Effectiveness of Stereotactic Ablative Radiotherapy for Systemic Therapy Respondents with Inoperable Pulmonary Oligometastases and Oligoprogression
por: Ho, Chin-Beng, et al.
Publicado: (2023)

Maximizing Benefits from Maintenance Pemetrexed with Stereotactic Ablative Radiotherapy in Oligoprogressive Non-Squamous Non-Small Cell Lung Cancer
por: Lu, Shao-Lun, et al.
Publicado: (2016)

Impacts of WNT1-inducible signaling pathway protein 1 polymorphism on hepatocellular carcinoma development
por: Chen, Chih-Tien, et al.
Publicado: (2018)

Risk Stratification Using a Novel Nomogram for 2190 EGFR-Mutant NSCLC Patients Receiving the First or Second Generation EGFR-TKI
por: Chang, John Wen-Cheng, et al.
Publicado: (2022)

Prior EGFR tyrosine-kinase inhibitor therapy did not influence the efficacy of subsequent pemetrexed plus platinum in advanced chemonaïve patients with EGFR-mutant lung adenocarcinoma
por: Tseng, Jeng-Sen, et al.
Publicado: (2014)

Comprehensive assessment of pretreatment sarcopenia impacts on patients with EGFR ‐mutated NSCLC treated with afatinib
por: Wu, Chen‐Te, et al.
Publicado: (2023)

Radiotherapy with continued EGFR‐TKIs for oligoprogressive disease in EGFR‐mutated non‐small cell lung cancer: A real‐world study
por: Hu, Chunhong, et al.
Publicado: (2022)

Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC)
por: Hsu, Ping-Chih, et al.
Publicado: (2019)

Oligoprogression in Non-Small Cell Lung Cancer
por: Harada, Daijiro, et al.
Publicado: (2021)

Influence of the Timing of Leptomeningeal Metastasis on the Outcome of EGFR-Mutant Lung Adenocarcinoma Patients and Predictors of Detectable EGFR Mutations in Cerebrospinal Fluid
por: Liao, Pei-Ya, et al.
Publicado: (2022)

Endovascular treatment in bilateral cavernous sinus dural arteriovenous fistulas: a systematic review and meta-analysis
por: Perng, Pang-Shuo, et al.
Publicado: (2023)

The Management of Oligoprogression in the Landscape of New Therapies for Metastatic Melanoma
por: Guida, Michele, et al.
Publicado: (2019)

PKCδ-mediated SGLT1 upregulation confers the acquired resistance of NSCLC to EGFR TKIs
por: Chen, Chia-Hung, et al.
Publicado: (2021)

An Update on Clinicopathological and Molecular Features of Plexiform Fibromyxoma
por: Su, Hsuan-An, et al.
Publicado: (2019)

Local microwave ablation with continued EGFR tyrosine kinase inhibitor as a treatment strategy in advanced non-small cell lung cancers that developed extra-central nervous system oligoprogressive disease during EGFR tyrosine kinase inhibitor treatment: A pilot study
por: Ni, Yang, et al.
Publicado: (2016)

Successful treatment of induced oligometastasis and repeated oligoprogression of advanced lung adenocarcinoma with immunotherapy and radiotherapy
por: Lee, Ho Young, et al.
Publicado: (2022)

Chrysophanol Regulates Cell Death, Metastasis, and Reactive Oxygen Species Production in Oral Cancer Cell Lines
por: Hsu, Po-Chih, et al.
Publicado: (2020)

Restricting Glutamine Uptake Enhances NSCLC Sensitivity to Third-Generation EGFR-TKI Almonertinib
por: Liu, Yaming, et al.
Publicado: (2021)

ALK variants, PD-L1 expression, and their association with outcomes in ALK-positive NSCLC patients
por: Chang, Gee-Chen, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_di00bmlkvq9ci2qmoq9r79nfi7